Roche Holding AG (TSX:ROG)
32.38
0.00 (0.00%)
Nov 17, 2026, 3:55 PM EST
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.45B CHF in the half year ending June 30, 2026, with 2.26% growth. This brings the company's total for the last twelve months to 62.96B, down -0.83% year-over-year. In the year 2025, Roche Holding AG had annual revenue of 63.36B with 1.54% growth.
Revenue (ttm)
62.96B CHF
Revenue Growth
-0.83%
P/S Ratio
4.94
Revenue / Employee
609.78K CHF
Employees
103,249
Market Cap
547.05B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Roche Holding AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.21B |
| Extendicare | 2.17B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| WELL Health Technologies | 1.56B |
| Sienna Senior Living | 1.11B |
| Vireo Growth | 956.44M |
| Knight Therapeutics | 563.45M |
Roche Holding AG News
- 1 day ago - Roche Secures First U.S. Approval for New Breast-Cancer Pill - WSJ
- 2 days ago - Genentech announces FDA approval of Wilserdly in combination with everolimus - TheFly
- 2 days ago - FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer - Business Wire
- 2 days ago - FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer - GlobeNewsWire
- 2 days ago - US FDA approves Roche's oral treatment for advanced breast cancer - Reuters
- 2 days ago - Roche receives FDA De Novo authorization for cobas pro i 601 platform - TheFly
- 2 days ago - Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories - PRNewsWire
- 2 days ago - Genentech announces FDA approval of Gazyva for primary membranous nephropathy - TheFly